UT-MD Anderson Cancer Center: ASH - Mantle Cell Lymphoma Patients See Improved Outcomes With Oral Combination of Ibrutinib and Venetoclax
December 13, 2023
December 13, 2023
HOUSTON, Texas, Dec. 13 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
MD Anderson-led Phase III trial demonstrates significantly improved progression-free survival and remission rates
* * *
The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS) and achieved an overall remission rate in 82% of patients with relapsed/refractory . . .
* * *
MD Anderson-led Phase III trial demonstrates significantly improved progression-free survival and remission rates
* * *
The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS) and achieved an overall remission rate in 82% of patients with relapsed/refractory . . .